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Objective: To compare the analgesic effect of surgical wound infiltration with liposomal 
bupivacaine (LB) to saline placebo in dogs after tibial plateau leveling osteotomy (TPLO).  
Study Design: Blinded, randomized, placebo-controlled clinical prospective study  
Animals: 15 client-owned dogs receiving liposomal bupivacaine and 17 dogs receiving an 
equivalent volume of saline placebo, all with confirmed unilateral cranial cruciate ligament 
insufficiency. 
Methods:  Preoperatively and up to 48 hours after surgery, Glasgow Composite Measure Short 
Form (CMPS-SF) pain scores were assigned and using a weight distribution platform, static body 
weight distribution (%BWdist) to the operated limb was measured. Postoperatively, dogs also 
received carprofen 2.2 mg/kg subcutaneously every 12 hours. Rescue analgesia was provided.  
Treatment success was defined as not requiring rescue analgesia over the 48 hour postoperative 
period.   
Results: There was no difference between treatment success, postoperative opioid consumption, 
CMPS-SF pain scores, or %BWdist in dogs that received surgical wound infiltration with LB 
compared with those receiving saline placebo, following TPLO.  There was no linear correlation 
between CMPS-SF pain scores and %BWdist.  
Conclusion: For the population of dogs that underwent TPLO and received postoperative 
carprofen at our institution, LB did not provide an analgesic effect discernable by success/failure 
analysis, CMPS-SF pain scores, or %BWdist measurement using a weight distribution platform, 
compared with saline placebo. 
Clinical Significance (or Impact): LB may not provide detectable analgesia for dogs 
recovering from TPLO and receiving postoperative carprofen.   
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Chapter 1 - Liposomal Bupivacaine Literature Review 
 An unmet need for bridging analgesia  
Maintaining adequate analgesia as veterinary patients are transitioned from hospital to 
home care is challenging.  In hospital, specialized equipment and trained staff enable 
implementation of multimodal postoperative analgesia protocols. For dogs undergoing 
orthopedic surgery, the World Small Animal Veterinary Association (WSAVA) Global Pain 
Council recommends that analgesic protocols include local/regional anesthesia, non-steroidal 
anti-inflammatory drugs (NSAIDs) and opioids used in the pre- and postoperative periods. The 
WSAVA also recommends adjunct analgesia, including preoperative alpha-2 agonists, a 
lidocaine patch or diffusion catheter, and cold therapy.1   
Provision of up to 24 hours of regional analgesia is possible with single-dose epidurals 
using morphine-bupivacaine 0.5% 2,3 or morphine-ropivacaine 1%4, as well as by femoral and 
sciatic blockade with 0.5% bupivacaine2 and saphenous or sciatic blockade with ropivacaine 
1%.5 As pain relief from epidural anesthesia or nerve blockade fades and the patient is weaned 
from injectable opioids, clinicians and owners may continue to use U.S. Food and Drug 
Administration (FDA) approved NSAIDs6 for dogs who remain appropriate candidates:1,7 those 
that continue to eat and drink normally, and that are not experiencing potential side effects.8  
For dogs that are not NSAID candidates, there are limited options for oral medications 
with evidence of efficacy in controlling acute orthopedic pain. A systematic review and meta-
analysis of the efficacy of tramadol for postoperative pain management in dogs concluded with 
moderate certainty that, compared with no treatment, the drug probably results in a reduction in 
the need for rescue analgesia.9 Among the oral medications tested in dogs after undergoing tibial 
plateau leveling osteotomy (TPLO) surgery specifically, pain scores in patients receiving either 
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hydrocodone-acetaminophen or tramadol were similar but were not compared to placebo or an 
FDA-approved positive control; 29% of all patients enrolled in that study required rescue 
analgesia.10 Another study found that hydrocodone provided inferior analgesia compared to 
firocoxib in dogs following TPLO surgery, with 50% of patients receiving extended-release 
hydrocodone requiring rescue analgesia vs. 11% needing rescue analgesia within the firocoxib 
group.  Pain scores were higher and percent body weight supported by the operated limb was 
lower for dogs receiving hydrocodone.11  To date, there are no published analgesic efficacy 
studies of oral codeine in dogs.  
Transdermal fentanyl delivery products come close to providing an ideal solution for 
postoperative pain relief in an outpatient setting. A single dose, sustained release, topical 
fentanyl solution gained FDA approval and became available in the United States in 201212.  The 
product provided therapeutic plasma levels of fentanyl within 2 to 12 hours of application, 
sustained for approximately four days13 and was shown to provide non-inferior analgesia 
compared with repeated injection of oxymorphone in a population of dogs undergoing soft-tissue 
or orthopedic surgeries.14  Unfortunately, the manufacturer no longer markets this product.  
Currently, clinicians may opt for extra-label use of transdermal fentanyl patches approved for use 
in humans. There is evidence for fentanyl patches providing sustained postoperative analgesia in 
dogs,15-17 but drawbacks of fentanyl patches include the delay of approximately 12-24 hours 
before reaching therapeutic plasma concentrations, potential variability in systemic absorption,18 
the possibility of overdose with oral transmucosal or enteral absorption,19,20 and the risk of 
accidental or intentional misuse by owners or visitors to the home. 
The challenge of providing safe, effective postoperative bridging analgesia is not unique 
to veterinary medicine.  While human physiology is such that oral opioid pain relievers (OPRs) 
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are effective for moderate to severe pain,21 their associations with adverse events, persistent use 
beyond the time of need, and addiction22 have led to an urgent call for the substitution of non-
opioid analgesics. 
A long-acting local anesthetic (LA) could provide a solution to this One Health need for 
safe, targeted and well-tolerated analgesic products that complement or substitute for opioids and 



















 Local anesthetic agents: mechanism of action, pharmacokinetics and toxicity 
Development of a long-acting LA product begins with an understanding of the molecular 
properties that influence mechanism of action, potency, duration of action and safe use. LAs 
provide temporary relief from pain by reversibly blocking sensation and motor function of 
peripheral nerves. Their primary mechanism of action is to block voltage-gated Na+ channels 
that exist in nerve cell membranes. In the presence of a therapeutic concentration of a LA, a 
stimulated nociceptor cannot depolarize enough to generate an action potential, so the sensation 
of pain will not propagate to the central nervous system to be modulated or perceived.23 LAs are 
the only class of analgesics that can block transmission of pain,24 preventing repeated stimulation 
of primary afferent neurons, thereby preventing central sensitization.25  
The mammalian LA receptor site (NaIII) exists within the inner pore of the Na+ channel. 
Some antiarrhythmic and anticonvulsant drugs also interact with NaIII,26  and our understanding 
of how these structurally diverse drugs can interact with a single binding site is still evolving.24,27  
The authors of a recent molecular dynamics study of diverse sodium channel blockers proposed a 
common pharmacophore, or set of general molecular features that a ligand must possess in order 
to interact with a receptor. The pharmacophore that describes known NaIII ligands consists of a 
cationic moiety (part of a molecule) and an aromatic moiety linked by an intermediate chain that 
is either an amide or an ester.  It is the cationic moiety that interacts with NaIII.  This binding 
interaction can be achieved directly by an ammonium functional group or by an electroneutal 
functional group that clamps a nearby sodium ion into the receptor.27 Drugs used historically28 
(such as cocaine) and currently (lidocaine, bupivacaine, ropivacaine) as LAs possess an 
ammonium functional group.  On the opposite end of the molecule, the aromatic moiety of a LA 
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interacts with a hydrophobic region of the inner Na+ channel pore, helping the ligand dock into 
the channel.27   
Physicochemical properties of LAs influence how these drugs move through the body 
from the site of injection.  Lipophilicity, degree of protein binding and vasoactivity are the major 
physiochemical properties that influence systemic absorption, and in turn, duration of effect. 
Highly lipophilic LAs tend to associate with the lipid-rich neural membrane and surrounding 
subcutaneous fat, resisting systemic absorption. Lipophilicity is a determinant of LA potency as 
well, as a more lipophilic drug is better able to permeate and diffuse across the neuron cell 
membrane, reaching its embedded sodium channels. The primary determinant of lipophilicity is 
the extent to which a molecule exists in a neutral, non-ionized state at physiologic pH – as 
opposed to its ionized, conjugate base state – as described by its partition coefficient.24,29 Among 
modern LAs commonly used in small animals, bupivacaine is more lipophilic than ropivacaine, 
which is more lipophilic than lidocaine.24,30,31 
A greater degree of protein binding is associated with longer duration of action, which is 
thought to be a result of a drug’s affinity for proteins within the sodium channel.31 Lidocaine has 
a moderate degree of protein binding, while bupivacaine/levobupivacaine, and ropivacaine are 
highly protein-bound.24  
Uptake of a drug into systemic circulation from its site of administration is slower if the 
local tissue is relatively avascular or if the local vasculature undergoes vasoconstriction.  Local 
anesthetics induce vasoconstriction at low doses and vasodilation at high doses. At therapeutic 
tissue concentrations, all aminoamide LAs produce some degree of vasoconstriction. 
Vasoconstriction potency is influenced primarily by lipophilicity, and to lesser degrees drug 
potency, pKa and molecular weight.  The vasoconstriction potency is greatest for 
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levobupivacaine, followed by ropivacaine and lidocaine.32 This effect contributes to the longer 
duration of action for levobupivacaine and ropivacaine compared with lidocaine. 
LAs can be administered by infiltration of local tissues, injection around peripheral 
nerves, or neuraxial injection.  LAs will also produce motor blockade when used peripherally or 
neuraxially24 – for example, when lumbosacral epidurals result in hind limb paralysis33 – which 
has intraoperative benefits but postoperative disadvantages in terms of patient mobility. Tissue 
infiltration of the surgical site with a LA provides targeted analgesia while avoiding motor 
blockade.34 
All local anesthetics have the potential to cause systemic effects, with signs of 
neurotoxicity preceding cardiovascular compromise.  Most severe toxicity events result from 
inadvertent intravascular injection of an appropriate dosage of local anesthetic, but it is possible 
for toxicity to follow large-volume tissue infiltration of LA.35  Humans may experience 
numbness of the tongue, lightheadedness, visual disturbances and muscle twitching initially. As 
plasma levels of local anesthetic increase, signs progress to seizure, coma and cardiac arrest.36  A 
similar progression is reported in animals.24 Bupivacaine is more cardiotoxic than lidocaine and 
ropivacaine. This is thought to be due primarily to its blockade of calcium channels in 
cardiomyocytes, slowing cardiac depolarization, shortening of the refractory period and 
decreasing contractility.37 35 Ropivacaine has lower potential for neurologic and cardiotoxicity in 
humans and animals compared to bupivacaine.24,36 
An ideal LA candidate for long acting, targeted postoperative pain relief without motor 
blockade would be lipophilic, highly protein-bound, and well tolerated. However, research and 
development efforts have not yet yielded a LA with an intrinsic duration of action beyond 
bupivacaine/levobupivacaine’s outer limit of 10 hours.24 Extension of the analgesia provided by 
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LA tissue infiltration therefore requires modification of the local tissue environment, use of 























 Prolonging duration of analgesia of local anesthetics  
One of the first techniques developed to prolong the duration of effect of a LA involves 
physically restricting its systemic absorption by use of a tourniquet, now known as intravenous 
regional anesthesia (IVRA).38 Bier first described this technique for use in human limb surgery 
in 1908, but IVRA did not become widespread until Holmes reintroduced it with some 
modifications in 1963.39  In dogs, the most recently reported use of an IVRA technique for 
surgery involved exsanguination of the forelimb with an elastic bandage applied distally to 
proximally, application of a non-pneumatic, pediatric tourniquet over the mid-antebrachium, 
then removal of the elastic bandage to establish an ischemic tissue environment. Regional 
anesthesia was produced by injection of lidocaine 0.5% solution (3 mg/kg) into the cephalic vein, 
10 minutes before performing pancarpal arthrodesis. This study showed that during an 
approximately one hour surgery, IVRA provided analgesia similar to traditional brachial plexus 
block with lidocaine/ropivacaine, without complications.  The study also demonstrated that 
within about 25 minutes of removing the tourniquet at the end of surgery, dogs began perceiving 
a pinching stimulus to their toes.40 IVRA modestly extends the duration of analgesia provided by 
a LA during surgery, but is not recommended beyond 90 minutes due to the risk of ischemic 
injury.41 IVRA is best used to extend analgesia for anesthetized animals, as awake animals do 
not tolerate tourniquets, and is not intended to provide bridging analgesia.  
A chemical tourniquet effect can be achieved in peripheral (as well as neuraxial sites) by 
the addition of a vasoconstricting drug such as epinephrine42,43 to LAs. 39,40 The mechanism of 
action is to decrease local blood flow via α1 receptor agonism. Addition of epinephrine to 
lidocaine for tissue infiltration in humans provided complete blockage of a pinprick sensation at 
5 hours in 50% of participants, while the lidocaine-only treatment failed to block the sensation in 
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all participants.42  In horses, the duration of analgesia for procaine was increased significantly 
(from 3 to 4 hours) by the addition of epinephrine in a hoof withdrawal heat latency model of 
analgesic efficacy.43  Studies are limited in veterinary species, and the addition of epinephrine to 
bupivacaine for local tissue infiltration has not been described.   
 Drug delivery systems have been developed to overcome the limited duration of 
action of single-dose LA tissue infiltration.  Continuous wound infiltration with local anesthetics 
using flexible, indwelling catheters has shown benefits similar to epidural and intravenous 
analgesia in a meta-analysis of humans recovering from laparotomy and sternotomy.44 The use of 
wound soaker catheters in postoperative dog and cat patients (mainly undergoing limb 
amputation) was described in a single retrospective case series as feasible and well-tolerated, 
with the most common complication being inadvertent disconnection of the catheter from the 
extension set (7.7%), followed by incisional infection (5.3%).  These patients received either 
continuous infusion with lidocaine or intermittent boluses of bupivacaine.45 While wound soaker 
catheters can be used to provide analgesia beyond the 24 hour outer limit of an epidural or nerve 
blockade, most clinicians would consider them inappropriate for continued use at home.45 
 FDA-approved patches coated with lidocaine-infused adhesive material have been 
developed for relief of local pain in people with postherpetic neuralgia, a complication involving 
allodynia after Herpes zoster infection.46 Lipoderm47 is one of a handful of FDA-approved 
patches that are labeled for application to intact skin for up to 12 hours of continuous wear per 
day. The patch is meant to be applied directly over the area of skin that is most painful, providing 
analgesia by direct diffusion of lidocaine.47  Minimal systemic absorption of lidocaine is 
described after application of lidocaine patches to humans,47 cats48 and dogs.49,50 There are a 
limited number of clinical studies of the patch’s efficacy in relieving acute postoperative pain in 
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humans, with no overall difference in pain scores, opioid consumption or length of hospital stay 
in treated patients.51 Application of peri-incisional 5% lidocaine patches did not result in lower 
post-operative pain scores compared to placebo patches in dogs that underwent 
ovariohysterectomy.52 In dogs undergoing hemilaminectomy for single acute compressive 
thoracolumbar intervertebral disc extrusion, application of 5% lidocaine patches along both sides 
of the surgical incision did not reduce rescue analgesia requirement or pain scores compared to 
placebo.53  Although lidocaine patches are easily placed, and are tolerated by dogs and cats for 

















 Evolution of liposomal drug delivery  
 Liposomal delivery of LAs may meet the needs for safe, targeted, bridging post-
surgical analgesia. The basic unit of a liposomal delivery system is the liposome, a microscopic 
vesicle composed of one or more concentric spherical phospholipid bilayers that enclose an 
aqueous central space. Having lipid and aqueous regions, a liposome is able to carry either 
lipophilic (associated with the lipid membrane) or hydrophilic drugs (trapped within the internal 
aqueous compartment).   When drugs are carried by liposomes, they are released as the vesicles 
eventually break down and are protected from early degradation and inactivation.  The liposome 
itself is pharmacologically inert, non-immunogenic and minimally toxic, as it is typically 
composed of natural phospholipids that are similar to mammalian cell membranes.54,55 
 Liposomal delivery systems were initially developed and launched for clinical use 
in the late 1980s and early 1990s to enhance the safety of intravenously delivered drugs with a 
narrow therapeutic index, such as doxorubicin and amphotericin.  This first generation of 
liposomes is now referred to as conventional liposomes. They consist of simple lipid bilayer 
vesicles, less than 1 micron in diameter, designed to carry an internal payload of water-soluble 
drugs.54  In studies involving mice and humans, liposomal doxorubicin was shown to have a 
longer circulation time and decreased uptake by the heart compared to the free drug, resulting in 
lower cardiotoxicity.56,57_ENREF_53 
Conventional liposomes were found to be eliminated by plasma opsonization (adsorption 
of proteins to the phospholipid surface) with subsequent phagocytosis by resident macrophages 
in the reticuloendothelial systems of the liver, spleen, kidneys, bone marrow, lungs and lymph 
nodes.55  This targeting of liposomes to monocytes and macrophages was inevitably turned to 
advantage – for instance, with therapeutic bombing of bacteria-laden macrophages with 
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liposomal antibiotics58 and administration of liposomal chemotherapeutics to patients with 
tumors of the liver and spleen.57  
 Subsequent generations of liposomes have been modified to evade phagocytosis 
and make drug targeting even more specific.54 Incorporation of polyethylene glycol (PEG) into 
the liposome shell helps the vesicles resist opsonization and evade recognition by macrophages, 
to prolong the duration of drugs in circulation, in order to improve accumulation in diseased 
tissues and reduce side effects. 59-61 Manipulation of the size and charge of the lipid membranes, 
addition of ligands such as antibodies, proteins and carbohydrates into the phospholipid bilayers 
allow more targeted drug delivery for chemotherapeutics, vaccines62 and pain medication.55,62-65  
 Liposome-based analgesia was introduced in 2004, with the FDA approval of 
extended release epidural morphine injection (DepoDur).66 Given as a single-dose lumbar 
epidural administration, this formulation provides 48 hours of analgesia (and sometimes nausea) 
following lower abdominal and lower extremity surgery in humans.67,68 DepoDur’s extended 
release of morphine was made possible by a novel liposomal delivery system, DepoFoam, which 
was developed to serve as a depot for sustained release of drugs into extravascular spaces. The 
basic unit of DepoFoam is the multivesicular liposome (MVL), a conglomerate of non-
concentric, closely-packed lipid bilayers.  The DepoFoam MVL is a 10 to 30 micron diameter 
complex of liposomes that constantly translate, merge and divide.69,70  
The modification that led to the development of the MVL was the addition of a neutral 
lipid (a triglyceride) to the standard amphipathic phospholipid solution that undergoes double 
emulsification to produce liposomes.  The triglyceride fills the tiny triangular spaces where the 
spherical lipid bilayers touch, stabilizing the junctions between individual vesicles.  Without this 
triglyceride filler, the emulsification process yields concentric spheres of liposomes that degrade 
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much more quickly than the honeycombed MVL liposomes. Encapsulated drug is released by 
two mechanisms: by permeation through the outermost bilayer membranes and by sudden escape 
as the outermost vesicles degrade. The rate of release of the active drug can be modified by 
altering the ratio of long-chain (more stabilizing for slow release) to short-chain (fast release) 
triglycerides added during production. Another means of slowing the rate of release of the active 
drug is to increase the osmolarity of the aqueous phase in which the drug is dissolved.69 
DepoFoam enabled the next leap in liposome-based analgesia: the first FDA-approved long-

















 Safety and Pharmacokinetics of liposomal bupivacaine  
Introduced in 2011 and still used widely for post-surgical pain in people, Exparel,71 
provides slow release of bupivacaine (13.3 mg/mL) from a DepoFoam carrier. Initial approval 
was for analgesia in adults after single-dose surgical site infiltration.70  The FDA has recently 
approved expansion of Exparel’s use for surgical site infiltration to patients over 6 years old, 
making it the first and only long-acting non-opioid analgesic available to pediatric patients.71  In 
2016, the FDA approved Nocita,72 a seemingly identical liposomal bupivacaine (13.3 mg/mL) 
product labeled for single-dose surgical site infiltration following cranial cruciate ligament 
surgery in dogs older than 5 months of age.73 In 2018, Exparel gained FDA approval for 
interscalene brachial plexus nerve block in adults; that year, Nocita gained FDA approval for use 
in peripheral nerve blockade before onychectomy in cats.74  A review of liposomal bupivacaine 
for regional anesthesia is beyond the scope of this thesis.  
In its safety and tolerability study for original FDA approval, Exparel was infiltrated by a 
moving needle technique into the deep and superficial subcutaneous tissues of rabbits and dogs.  
The tissue layers were closed over polypropylene mesh in an inguinal hernia repair model.  
Exparel dosages ranged from 9 to 30 mg/kg, compared with a control group receiving 9 mg/kg 
non-liposomal bupivacaine. One rabbit died after receiving a 9 mg/kg dose of Exparel, which 
was attributed to systemic toxicity in a particularly sensitive species.  On histopathologic 
analysis, there was no evidence of local tissue toxicity in rabbits or dogs receiving Exparel.  In 
8/24 rabbits receiving Exparel, surgical site tissues sampled at 15 days showed minimal to mild 
granulomatous inflammation, consistent with a foreign body-type reaction. The authors called 
this a normal reaction to the liposomal component of the drug, rather than an adverse reaction. 
All surgical wounds healed as expected.75  
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In this safety study, pharmacokinetics of Exparel was favorable. Peak plasma 
concentrations resulting from Exparel at 9 mg/kg were lower than from non-liposomal 
bupivacaine at 9 mg/kg (about 1.7 and 5.8 times lower in rabbits and dogs, respectively). The 
peak plasma concentration of bupivacaine in animals receiving 30 mg/kg bupivacaine Exparel 
was lower than that of animals receiving 9 mg/kg non-liposomal bupivacaine. Based on 
pharmacokinetic area under the curve (AUC) comparisons, plasma concentrations were indeed 
sustained for animals receiving Exparel. These data demonstrated that Exparel provides 
sustained release of bupivacaine after tissue infiltration in rabbits and dogs, with greater 
morbidity and mortality in rabbits than in dogs. 75 
In people, plasma concentration of Exparel was characterized as bimodal, with an initial 
peak at ¼ to 2 hours and a second peak at 12 to 24 hours. The initial peak was thought to be due 
to the known presence of a small fraction of free (extraliposomal) bupivacaine in the 
suspension.76  Although peak plasma concentrations were higher and half-life was longer in 
patients with moderate hepatic impairment, the differences were not clinically significant and 
dose adjustments were not recommended.70  In contrast to the post-injection granulomatous 
inflammation described in rabbits, similar pathology has not been reported in humans dosed with 
Exparel.77  
The safety of Nocita for surgical site infiltration was evaluated in 123 dogs following 
either tibial plateau leveling osteotomy, lateral suture stabilization or tibial tuberosity 
advancement.  A control group of 59 dogs received an equal volume of saline placebo. For 
treated dogs, the three most common adverse events were: discharge from the incision (3.3% 
incidence), gross incisional inflammation (2.4%), and vomiting (2.4%). For dogs receiving 
placebo, no patients experienced those events; the three most common adverse events were 
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surgical limb edema +/- erythema (5.1%), soft stool/diarrhea (1.7%) and inappetence (1.7%).  
Statistical significance of these events was not described.73   
In a separate safety study evaluating effects of repeated dosing, Nocita tissue infiltration 
twice weekly at doses of 5.3, 16 and 26.6 mg/kg did not result in signs of systemic toxicity nor 
electrocardiogram abnormalities in the study dogs.  Granulomatous inflammation was observed 
in at least one dog in each of the Nocita groups, and this was described as a normal tissue 
response to the liposome component of the drug. The FDA determined Nocita to be safe for 

















 Clinical efficacy of liposomal bupivacaine in humans and animals  
 Clinical efficacy of LB has been extensively studied in humans. A 2021 
systematic review of 63 randomized clinical trials (RCTs) evaluated the post-surgical analgesic 
efficacy of liposomal bupivacaine used for local tissue infiltration or nerve block in humans. The 
distribution of studies by surgical specialty was: 33 orthopedic-related studies, 10 for general 
surgery, 9 for obstetric/gynecology, 4 for oral/maxillofacial surgery and 7 others. The review 
concluded that LB did not significantly reduce pain scores compared with placebo, standard 
bupivacaine or standard-of-care, non-bupivacaine analgesic agent in 74.58% of studies.  In 4 out 
of 10 studies of analgesic efficacy comparing LB to placebo, pain scores were not significantly 
different between the two groups.  In 20 out of 29 studies comparing LB to standard bupivacaine, 
pain scores were not significantly lower for people receiving LB.  Pain scores did not differ 
between treatment groups in any of the 16 studies comparing LB with non-bupivacaine 
analgesic.78   
 In this review, surgical specialty was associated with the probability of LB 
providing superior pain relief.  LB performed particularly poorly with respect to total knee 
arthroplasty, with a reduction of pain in only 2 out of 20 studies – one using LB vs. standard 
bupivacaine for local tissue infiltration79 and another using LB vs. placebo for femoral nerve 
block.80  
Among the 56 studies in the review that evaluated opioid use, LB did not result in 
significantly decreased postoperative opioid consumption in 85.71%, regardless of the 
comparative agent (placebo, standard bupivacaine or non-bupivacaine analgesia).78 
Furthermore, this review found that clinical trials disclosing a financial or employee 
relationship with the manufacturer of LB were over 14 times more likely to be associated with a 
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superior treatment effect of LB (OR: 14.31 [95% CI, 2.8, 73.10], P = 0.0001) and over 12 times 
more likely to report decreased opioid consumption in patients receiving LB (OR: 12.35 [95% CI 
1.40, 109.07], P = 0.0237). In light of these findings, the authors expressed concern about 
financial conflict of interest possibly having an influence on outcomes of RCTs, however they 
could not test causation. 
Another concern expressed by these authors was the underreporting of trial results. Of the 
total number government-registered RCTs that were started, 46.7% were either completed 
without published results or were never completed.  Publication bias for studies with positive 
outcomes is recognized in anesthesia literature81 and across other disciplines.82 The authors 
warned practitioners to consider publication bias when interpreting results indicating superiority 
of LB.78 Since Exparel costs more than standard bupivacaine, its use cannot be justified in 
humans if it does not provide superior analgesia, reduce opioid consumption or reduce hospital 
readmissions in comparison to placebo or standard of care protocols. 
In dogs, the analgesic efficacy of surgical site infiltration with Nocita has been reported 
in two clinical trials. In a randomized, placebo-controlled, masked study,83 LB was shown to 
provide local analgesia in dogs following lateral retinacular suture placement with arthrotomy. 
Outcome measures included subjective pain scores based on the short-form Glasgow Composite 
Measure Pain Scale (CMPS-SF)84 and success/failure analysis. Pain scores were lower for dogs 
receiving LB versus saline placebo at all time points (0 to 60 hours) post-operatively except at 72 
hours, at which time only two dogs remained in the placebo group.  Treatment success, defined 
as percent of dogs not requiring rescue analgesia, was significantly higher for dogs receiving LB 
versus placebo over the 0-24, 0-48 and 0-72 hour post-operative intervals. This study was funded 
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by the manufacturer of Nocita, the corresponding author was a paid consultant and two of the 
authors were employees of said manufacturer.83   
     A subsequent randomized, masked clinical study evaluated analgesic efficacy of 
surgical site infiltration with LB compared with standard bupivacaine in dogs recovering from 
tibial plateau leveling osteotomy (TPLO) with arthrotomy. In addition to pain scoring with the 
CMPS-SF and the Colorado State University Canine Acute Pain Scale85 (CSU-CAPS), this study 
used pressure nociceptive threshold (PNT) testing as an objective outcome measure of pain. A 
commercially available pressure algometer was used to apply force to over the medial joint space 
of the stifle, measuring maximum tolerated pressure before and at various times after surgery. 
Over the 48-hour postoperative period, dogs administered LB at wound closure were less likely 
to need rescue analgesia.  Total opioid consumption was reduced in the LB group as well.86  The 
opioid-sparing benefit conferred by LB was attributed to the longer duration of effect83 for that 
drug compared with standard bupivacaine.87 Interestingly, neither pressure threshold 
measurements nor pain scores differed significantly between treatment groups at any time point. 










 Conclusions and rationale for further research 
There is a need within human and veterinary medicine for safe, targeted and well-
tolerated analgesic products that complement or substitute for opioids and NSAIDs in patients 
transitioning to home care.  Standard formulations of LAs and current LA delivery systems fall 
short of meeting this need for bridging analgesia.     
Both clinical studies of LB efficacy in dogs83,86 found that LB reduced the requirement 
for rescue analgesia, however the more recent study did not find that LB had a significant effect 
on pain scores or PNT values.  There were differences in methodology between these studies that 
may have contributed to the difference in results.  First, TPLO surgery performed in the second 
study may have incited pain at a deeper anatomic location than the pain inflicted by the lateral 
suture stabilization performed in the first surgery.  Since LB is not administered into bone 
marrow or periosteum, perhaps the analgesia provided by LB could be less complete for dogs 
recovering from TPLO.   Second, LB was not compared to placebo in the more recent study, so it 
is possible that the treatment effect of LB and standard bupivacaine were not different enough to 
be discriminated by pain scoring or PNT.  Third, dogs in the second study received twice-daily 
carprofen as adjunct analgesia, while the dogs in the first study had received no adjunct analgesia 
postoperatively.  The background analgesia provided by carprofen may have blunted the 
treatment effect detected by pain scoring and PNT.    
As TPLO is commonly performed orthopedic procedures performed in dogs, finding a 
positive treatment effect of LB in dogs recovering from TPLO could benefit many animals.  
Conversely, finding a negative treatment effect could save owners considerable expense.  To 
date, there are no reported randomized, placebo-controlled, masked clinical trials without 
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Objective: To compare the analgesic effect of surgical wound infiltration with liposomal 
bupivacaine (LB) to saline placebo in dogs after tibial plateau leveling osteotomy (TPLO).  
Study Design: Blinded, randomized, placebo-controlled clinical prospective study  
Animals: 15 client-owned dogs receiving liposomal bupivacaine and 17 dogs receiving an 
equivalent volume of saline placebo, all with confirmed unilateral cranial cruciate ligament 
insufficiency. 
Methods:  Preoperatively and up to 48 hours after surgery, Glasgow Composite Measure Short 
Form (CMPS-SF) pain scores were assigned and using a weight distribution platform, static body 
weight distribution (%BWdist) to the operated limb was measured. Postoperatively, dogs also 
received carprofen 2.2 mg/kg subcutaneously every 12 hours. Rescue analgesia was provided.  
Treatment success was defined as not requiring rescue analgesia over the 48-hour postoperative 
period.   
Results: There was no difference between treatment success, postoperative opioid consumption, 
CMPS-SF pain scores, or %BWdist in dogs that received surgical wound infiltration with LB 
compared with those receiving saline placebo, following TPLO.  There was no linear correlation 
between CMPS-SF pain scores and %BWdist.  
Conclusion: For the population of dogs that underwent TPLO and received postoperative 
carprofen at our institution, LB did not provide an analgesic effect discernable by success/failure 
analysis, CMPS-SF pain scores, or %BWdist measurement using a weight distribution platform, 
compared with saline placebo. 
Clinical Significance (or Impact): LB may not provide detectable analgesia for dogs recovering 
from TPLO and receiving postoperative carprofen.    
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 Introduction 
A challenge of the immediate postoperative period is maintaining adequate analgesia as 
veterinary patients are transitioned from hospital to home care. As pain relief from local 
anesthetic tissue infiltration, epidural anesthesia or nerve blockade fades and the patient is 
weaned from injectable opioids, FDA-approved non-steroidal anti-inflammatory drugs 
(NSAIDs) are available for continued analgesia.1 For dogs that are not NSAID candidates,2-4 oral 
narcotics and lidocaine patches are available, but evidence of their efficacy in controlling acute 
postoperative pain is lacking.5-9  There is evidence for fentanyl patches providing sustained 
postoperative analgesia in dogs10-12 but drawbacks include a delay of about 12-24 hours to reach 
therapeutic plasma concentrations, variability in systemic absorption,13 the possibility of 
overdose with oral transmucosal or enteral absorption,14,15 and the risk of accidental or 
intentional misuse by owners or visitors to the home.16,17  
The need for safe, targeted and well-tolerated analgesic products for postoperative pain 
relief in humans and animals has led to the development of FDA-approved liposomal 
bupivacaine (LB) products that provide extended release of the local anesthetic into infiltrated 
tissues.18,19 The efficacy of LB in reducing pain scores and opioid consumption in people 
recovering from surgery was evaluated in a 2021 systematic review of 63 randomized clinical 
trials (RCTs). LB did not significantly reduce pain scores compared with placebo, standard 
bupivacaine or non-bupivacaine analgesic agent in 74.58% of studies measuring pain.  LB failed 
to reduce postoperative opioid consumption in 85.71% of studies evaluating opioid use.  
Furthermore, this review found that clinical trials disclosing a financial or employee relationship 
with the manufacturer of LB were 14.31 times more likely show pain relief and 12.35 times more 
likely to report decreased opioid consumption in patients receiving LB.20 
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 In dogs, the analgesic efficacy of single-dose surgical site infiltration with LB 
(Nocita; Elanco Animal Health, Greenfield, Indiana) has been reported in two clinical trials. The 
first was a randomized, placebo-controlled, blinded study of LB use in dogs after lateral 
retinacular suture placement with arthrotomy. Dogs receiving LB were less likely to require 
rescue analgesia and had lower pain scores between 0 and 60 hours after surgery, based on the 
short-form Glasgow Composite Measure Pain Scale (CMPS-SF).21,22 This study disclosed 
financial relationships with the manufacturer of Nocita.21  
A subsequent randomized, masked clinical study evaluated the efficacy of surgical site 
infiltration with LB compared with standard bupivacaine in dogs receiving carprofen after tibial 
plateau leveling osteotomy (TPLO) with arthrotomy. In addition to pain scoring with the CMPS-
SF and the Colorado State University Canine Acute Pain Scale (CSU-CAPS),23 this study used a 
pressure algometer to measure mechanical thresholds as an objective measure of pain. Over the 
48-hour postoperative period, dogs administered LB were less likely to need rescue analgesia 
and had reduced opioid consumption. However, neither pain scores nor pressure nociceptive 
threshold measurements were different between treatment groups at any time point. This study 
reported no financial conflicts of interest.24   
Further exploration of an objective outcome measure sensitive to acute postoperative 
orthopedic pain is therefore warranted.  An emerging objective measure of limb pain in dogs is 
%BWdist, the percentage of total body weight supported by a given limb at a natural stance. 
Measurements of %BWdist have shown consistency over time, sensitivity to limb lameness, and 
changes in limb use after TPLO and total hip arthroplasty. 25,26 27-31 To our knowledge, no study 
has compared %BWdist with subjective pain scores in dogs; this seems a rational next step in 
evaluating whether  %BWdist is an appropriate outcome measure of acute postoperative pain. 
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  As TPLO is one of the most commonly performed orthopedic procedures 
performed in dogs, finding a positive treatment effect of LB in dogs recovering from TPLO 
could benefit many animals.  Conversely, finding a negative treatment effect could eliminate 
unnecessary client expenses. To date, there are no reported randomized, placebo-controlled, 
masked clinical trials that evaluate the efficacy of LB in dogs undergoing TPLO.  
 The prospective study reported here was conducted to compare outcomes of 
client-owned dogs receiving carprofen and single-dose tissue infiltration with LB or saline 
placebo after undergoing TPLO. Our objectives were to (1) compare CMPS-SF pain scores 
between treatment groups at time points up to 48 hours postoperatively; (2) compare the need for 
rescue analgesia between groups during the first 48 hours postoperatively; (3) compare the 
number of rescue opioid doses relative to treatment group size (4) compare %BWdist between 
treatment groups up to 48 hours postoperatively; and (5) describe the statistical relationship 
between CMPS-SF pain scores and %BWdist.  The null hypotheses we tested were that: no 
significant difference would exist between CMPS-SF pain scores or %BWdist for the treatment 
groups at any time point; no difference would exist between treatment groups over the duration 
of the study for rate of treatment success or the number of rescue opioid doses relative to group 
size: and that no meaningful statistical relationship would exist between %BWdist and CMPS-SF 







 Materials and Methods 
Dogs  
Client-owned dogs scheduled for TPLO between July 2019 and July 2020 for confirmed 
unilateral cranial cruciate ligament (CCL) insufficiency of any duration were eligible for 
inclusion in the study. The study was approved by our institution’s animal care and use 
committee. Written informed owner consent was obtained for all enrollees. Screening was 
completed on the day before surgery, and candidates were subject to physical and orthopedic 
examinations, brief sedation for tibia/fibula radiographs for surgical planning, and hematologic 
analysis (complete blood cell count and serum biochemistry). Exclusion criteria were: age less 
than 1 year; current or historic bilateral CCL insufficiency; other clinically evident orthopedic 
disease; neurologic disease; uncontrolled diagnosed or clinically suspected systemic disease; any 
surgery within the previous 14 days; short acting corticosteroid use within the previous 7 days or 
repository steroid use within the previous 2 months; NSAID use other than carprofen within the 
previous 7 days; use of other analgesics within the previous 48 hours; and temperament that 
might interfere with subjective pain scoring or stance analysis. Demographic information 
gathered included unique patient identifier, age, sex, breed, body weight, affected hind limb, and 
estimated duration of lameness.  
 
Experimental Design 
This was a prospective, blinded, randomized, placebo-controlled analgesic efficacy study 
with CMPS-SF pain scores and %BWdist the primary outcome measures. Dogs were allocated 
into LB treatment and saline control groups by randomized stratification.  Dogs presenting to our 
institution for TPLO have commonly received a recent dose of the NSAID, carprofen. To avoid a 
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confounding effect on postoperative pain measurement, we stratified enrollees by carprofen use 
into “recent carprofen” (within the last 40 hours, representing approximately 5 terminal plasma 
half-lives)32 or “no recent carprofen” groups. Dogs within these groups were randomly assigned 
to either the LB or placebo treatment subgroups using a computerized random selection 
generator (randomizer.org).  
    Data from pain scoring and %BWdist measurement were collected preoperatively 
(before sedation for TPLO planning radiographs) and over the 48-hour postoperative study 
duration by two investigators (L.A., I.O.) who were blinded to treatment assignment.  
 
CMPS-SF  
The CMPS-SF is a subjective clinical metrology instrument designed for efficient 
assessment of acute postoperative pain in dogs in a clinical setting.22  Through a combination of 
observation and interaction across six behavioral categories, a total pain score is assigned 
between 0 and 24 for ambulatory patients, or between 0 and 20 for patients who cannot walk 
without assistance. Two investigators (L.A. and I.O.) trained together in use of the CMPS-SF for 
several days before the study began, to achieve subjective interobserver consistency in scoring of 
postoperative orthopedic surgery patients.  Pain scores for study participants were assigned by 
one of these two investigators preoperatively (baseline) and at 2, 4, 8, 12, 20, 24, 32, 40, and 48 
hours postoperatively, where 0 hours was time of extubation. 
 
Static body weight distribution 
Data from body weight distribution measurement were collected by one of two 
investigators (L.A. and I.O.) at baseline and at 4, 12, 24 and 48 hours postoperatively using a 
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weight distribution platform (PetSafe Stance Analyzer, Companion Animal Health, Newark, DE, 
USA). At the start of each session, the platform and associated software were calibrated to zero 
weight. Based on previous studies of the repeatability of stance analysis,25,27 the patient was 
walked at a velocity of approximately 1 m/s onto the soft plastic platform, led on a short neck 
leash by an investigator positioned to the animal’s right.  The dog was abruptly stopped as the 
investigator moved in front of the animal to discourage additional forward movement.  This 
procedure was repeated if the dog sat, lay down, or did not otherwise assume a natural, square 
stance with one foot upon each of the quadrants of the platform and its head held approximately 
on midline. After the dog maintained a square stance for appoximately 5 seconds, data collection 
was started, with multiple measurements of body weight distribution to each limb captured at 
approximately 0.5 to 1 second intervals, using a handheld remote control. Outlier measurements 
resulting from aberrant body movements were immediately discarded and 6 valid measurements 
per session were obtained, from which mean %BWdist was calculated for the operated limb. 
When pain scoring and %BWdist measurement were scheduled at concurrent time points, pain 
scoring was completed first.   
 
Rescue analgesia, success/failure determination, and mean rescue opioid doses 
Dogs were administered a single dose of hydromorphone 0.08 mg/kg subcutaneously as 
rescue analgesia if they were assigned a CMPS-SF pain score of 6/24 or 5/20 or greater during 
any of the scheduled or unscheduled (clinically indicated) pain assessments based on previous 
recommendations.13After a dog received rescue analgesia, all subsequent pain scores and 




Anesthesia, analgesia and surgery 
All dogs were premedicated with IM administration of acepromazine (0.01 to 0.02 
mg/kg) and hydromorphone (0.08 to 0.1 mg/kg). Anesthesia was induced with intravenous 
propofol and maintained with isoflurane in oxygen, both given to effect. No regional adjunct 
anesthetic techniques such as lumbosacral epidural or nerve blockade were permitted.  All dogs 
received cefazolin (22 mg/kg) IV and IM at induction of anesthesia, as well as intravenous fluid 
therapy during the anesthetic period. Treatments for systemic hypotension under anesthesia 
included fluid therapy, antimuscarinics and adrenergic agonists, as needed.  
Routine TPLO33 was performed by one of eight primary surgeons, including residents, 
ACVS board-eligible and ACVS board-certified surgeons.  Based on surgeon preference 
regarding stifle joint exploration and meniscal cartilage treatment, any of the following 
procedural variations were permitted: craniomedial parapatellar arthrotomy, cranial cruciate 
ligament debridement, meniscal debridement, or midbody outside-to-inside medial meniscal 
release.34 
After stabilization of the osteotomy and closure of the joint capsule, the surgical wound 
was infiltrated with either undiluted LB (5.3 mg/kg;0.4 mL/kg) or an equal volume of sterile 
saline (0.4 mL/kg), based on the patient’s random group assignment. The infiltrate was 
administered using the moving needle technique21 using a sterile syringe fitted with a 1.0 to 1.5 
inch, 22-gauge needle. The entire volume was distributed into three tissue layers as described in 
previous LB efficacy studies21,24 with approximately 25%, 50% and 25% injected into the 
superficial tissues of the closed joint capsule, the closed fascial tissue, and the subcuticular 
tissue, respectively, before skin closure.  No surgeon found it necessary to dilute the LB with 
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saline to achieve full coverage of the surgical site. The investigator who performed TPLO 
surgery in addition to postoperative pain assessment (L.A.) remained blinded to the treatment by 
exiting the surgical suite after stabilizing the osteotomy and closing of the joint capsule, allowing 
an alternate surgeon to perform tissue infiltration and closure. 
When skin apposition was complete, the patient received a single dose of IV 
hydromorphone (0.08 mg/kg).  Postoperative radiographs were performed routinely under 
general anesthesia. During the 48-hour postoperative study period, all dogs received 
subcutaneous carprofen (2.2 mg/kg) every 12 hours, beginning at time of extubation (0 hours). 
When a carprofen dose was scheduled concurrently with pain scoring and %BWdist measurement, 
data were collected before carprofen was administered.  Dogs experiencing significant dysphoria 
upon recovery were permitted to receive a single IV dose of dexmedetomidine (1 mcg/kg) at the 
discretion of the supervising anesthesiologist.  
Postoperative care included leash walks every 4 hours, free access to water, meals offered 
every 12 hours, and icing of the incision site every 4 hours between 7am and 11pm. The surgical 
incision was protected with a bandage consisting of a non-adherent dressing with an adhesive 
covering until time of discharge. Dogs wore an Elizabethan collar at all times. Adverse events 
were noted and addressed.   
 
Sample size calculation 
Sufficient raw data are not previously reported describing static body weight distribution 
in dogs in the acute postoperative period, making a priori power analysis for sample size 
calculation a challenge. The kinetic variable, peak vertical force (PVF), and %BWdist were 
shown to have similar sensitivity to detecting change in hind limb use before and approximately 
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4 months after total hip replacement.27  To estimate an expected effect size of %BWdist for LB 
compared to placebo, we calculated an effect size of changes in PVF ratios reported in a previous 
analgesic efficacy study.35  Pain intensity for the induced synovitis model used in that study was 
expected to peak at 2-3 hours after urate crystal injection.36 At 3 hours after urate crystal 
injection, PVF ratios were significantly different between firocoxib and placebo groups35 and the 
effect size was large (Cohen’s d = 1.4, effect size index for two-tailed t-test of means).  Using 
that effect size, a priori power analysis yields a sample size of 30 dogs (15 in each treatment 
group), at a power (1-β) of 0.95 and significance (α) of 0.05. 
 
Statistical analysis 
Comparisons of pertinent treatment group variables including recent carprofen use and 
frequencies of arthrotomy and meniscal debridement were performed using a Chi-square test. 
Pain scores were compared between treatment groups preoperatively and at 2, 4, 8, 12, 20, 24, 
32, 40 and 48 hours postoperatively with a nonparametric Mann-Whitney U test. Treatment 
success for a patient was defined as not requiring any rescue analgesia within the entire 48 hour 
postoperative period. The proportion of successes vs. failures between treatment groups was 
compared with a Chi-square test. A comparison between the number of required rescue opioid 
doses relative to treatment group size was made using a nonparametric Mann-Whitney U test. 
Data describing %BWdist for the operated hind limb were determined to be normally distributed 
(p = 0.001) by use of the Anderson-Darling test.  %BWdist values were compared between 
treatment groups preoperatively and at 4, 12, 24, and 48 hours postoperatively with a Student’s T 
test. Linear relationship between pain score and %BWdist was assessed using Pearson’s 
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correlation coefficient. Pain Scores and %BW values were excluded from analysis after rescue 
























Thirty-two dogs were enrolled and all completed the study. Fifteen (15) dogs were treated 
with LB and 17 with saline placebo. Frequencies of recent carprofen use (P = 0.39), arthrotomy 
(P = 0.54), and meniscal debridement (P = 0.31) (Table 1) were not different between treatment 
groups.   
 
Pain scores 
Median CMPS-SF pain scores at preoperative baseline were 1 (range 1-5) and 1 (range 1-
3) for the LB and saline groups, respectively (P = 0.82).  Median pain scores did not differ 
between treatment groups at any postoperative time point (Table 2). 
 
Success/failure analysis 
Overall treatment success was not different between dogs that received LB and those that 
received placebo (chi square P = 0.27) (Table 3). Two out of 15 dogs in the LB group required 
rescue analgesia, both at 2 hours postoperatively.  Five out of 17 dogs in the placebo group 
required rescue analgesia: 4 dogs at 2 hours postoperatively, and 1 dog at 8 hours 
postoperatively.  
 
Rescue opioid doses 
The number of rescue opioid doses did not differ between the treatment groups, with the 
LB group (n = 15) receiving 3 total opioid doses and the placebo group (n = 17) receiving 10 




   Mean %BWdist values for the operated hind limb at preoperative baseline did not differ 
between the LB (6.7 ± 4.0%) and placebo (7.5 ± 4.7%)  (P = 0.61) any postoperative time point.  
(Table 4).  %BWdist data was unable to be collected at three postoperative time points for the 25 
dogs that did not require rescue analgesia. One dog was too sedate to stand at 4 hours 
postoperatively and two dogs repeatedly chose to sit or lay down upon reaching the weight 
distribution platform at 48 hours postoperatively and could not be encouraged to stand. For the 7 
dogs that required rescue analgesia, concurrent and subsequent %BWdist values were excluded 
from statistical analyses. 
 
Relationship between pain score and %BWdist  
   Analysis of linear correlation between CMPS-SF pain scores and %BWdist pooled to 
include all study participants did not demonstrate a statistically significant relationship at any 
time point, with Pearson’s r values of 0.11, 0.23, 0.02, -0.24, -0.19 at preoperative baseline, and 
4, 12, 24 and 48 hours, respectively. 
 
Adverse events 
   Adverse postoperative events were observed in 5 dogs during the study; 3 in the LB 
group and 2 in the placebo group.  Within the LB group, two dogs had incisional complications.  
One dog was noted to have bandage strikethrough at 4, 8 and 20 hours postoperatively that 
resolved with placement of a soft padded compression bandage.  Another dog had focal 
serosanguineous discharge at 24 hours postoperatively that resolved with placement of a single 
surgical staple to improve skin apposition.  One dog in the LB group became mildly cage 
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aggressive and less cooperative over time, however we were able to complete pain scoring and 
body weight distribution measurements.  Within the placebo group, one dog regurgitated at 42 
hours postoperatively and another dog was noted to have soft but formed stool.   
    
Post hoc sample size calculation 
   The size of the treatment effect observed for %BWdist was smaller than estimated 
before the study was initiated.  Effect size (Cohen’s d) for %BWdist ranged from 0.27 to 0.75; at a 
power (1-β) of 0.80 and significance (α) of 0.05, a total of 58 to 436 dogs would have been 

















   Results of this study show no difference between treatment success, postoperative 
rescue opioid consumption, CMPS-SF pain scores, or %BWdist in dogs receiving carprofen and 
single-dose surgical wound infiltration with either LB or saline placebo, after TPLO.  Therefore, 
we could not reject any of our null hypotheses. In the absence of any observed treatment effect, 
our first concern is to address the possibility that a type II error was committed. To calculate 
sample size prior to the study, we used an estimated treatment effect for %BWdist that turned out 
to be much greater than the actual treatment effect that we observed for %BWdist. Enrolling 
between 58 to 436 dogs into the study within a reasonable time frame would have been very 
challenging.  
Using 46 and 29 dogs, respectively, two previous clinical studies21,24 both found that dogs 
administered LB were less likely to require rescue analgesia after stifle surgery. The first was a 
pilot, randomized, placebo-controlled, masked study of dogs undergoing lateral retinacular 
suture placement with arthrotomy. The percent of dogs requiring rescue analgesia was 
significantly lower for dogs receiving LB versus placebo over 0-24, 0-48 and 0-72 hour post-
operative intervals.21 Although the extent of the soft tissue approach is similar between TPLO 
and lateral retinacular suture placement, TPLO involves greater surgical trauma.  It is possible 
that periosteal and bone marrow pain are not well controlled by LB, especially if it does not 
penetrate deeper than the soft tissues into which it is injected.  In addition, dogs in the pilot study 
received no scheduled analgesia following a single dose of hydromorphone given before 
induction of anesthesia.  In our study, carprofen was administered every 12 hours, 
postoperatively.  The clinical benefit of LB for TPLO-induced pain in dogs already receiving 
carprofen therefore comes into question.  
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A subsequent randomized, blinded study24 incorporated carprofen into its postoperative 
analgesia protocol for dogs that received either LB or 0.5% bupivacaine surgical site infiltration 
for TPLO with arthrotomy. There was an opioid-sparing benefit of LB in the face of background 
treatment with carprofen.  Over the 48 hour postoperative period, dogs administered LB at 
wound closure were less likely to need rescue analgesia and consumed a lower total morphine 
equivalent for rescue analgesia.24 The opioid-reducing benefit conferred by LB was attributed to 
its longer duration of effect compared with standard bupivacaine.  Although this study showed a 
clinical benefit of LB beyond that achieved by carprofen alone, we cannot directly compare their 
treatment success analysis with our own.  This is because the decision to provide rescue 
analgesia in that study was based on pain scores using assigned by the CSU-CAPS, rather than 
the with the CMPS-SF. The authors argued24 that CMPS-SF scores can be increased by signs of 
anxiety in dogs. For this reason, the CMPS-SF analgesic intervention score remains 
controversial. It is worth noting that while the LB pilot study used the CMPS-SF to identify 
patients needing rescue analgesia, the intervention level was raised from a suggested 6/24 to 8/24 
based on investigator experience.21  
Subjective pain scales are limited in their ability to describe the magnitude of pain relief 
provided by the treatment compared to placebo, but they are regarded as the current gold 
standard for evaluating pain in animals.  The original, longer form of the CMPS37 has been 
shown to have criterion validity, demonstrating sensitivity to acute post-operative pain in dogs in 
a clinical setting.38 While the CMPS-SF was derived from the CMPS to help clinicians more 
efficiently identify acute pain and implement rescue analgesia in dogs, it has not undergone 
criterion validation. In this and previous studies, background analgesia has been minimized to 
improve the sensitivity of the CMPS-SF to treatment effect.  Similar to findings in the previous 
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LB for TPLO study24, pain scores in our study were not different for dogs receiving LB 
compared to control at any time point. The background effect of the carprofen given to the dogs 
in these studies may have obscured the ability to detect a clinical benefit of LB.  We could have 
eliminated the background analgesic effect of the NSAID in the present study, but we considered 
it clinically valuable to determine whether LB might provide detectable analgesia beyond that of 
carprofen.  In addition, while it was appropriate to exclude from analysis the subsequent pain 
scores of dogs that received rescue analgesia, this also decreased our sample population size and 
the power of the study over time. Another limitation of the study with respect to pain scoring was 
that we did not statistically test interobserver agreement between the two investigators during the 
pre-study training period. 
    It is interesting that objective means of pain assessment in the present and previous LB 
for TPLO study24 failed to demonstrate a difference in outcome for dogs receiving LB.  In the 
previous TPLO study, mechanical nociceptive threshold values did not differ between dogs that 
received LB compared with 0.5% bupivacaine. It is possible that the treatment effects of LB and 
standard bupivacaine were truly not different enough to be discriminated by pain scoring or 
pressure algometry. It is also possible that individual variability in responses to algometry39 or 
learned aversion to the algometer with repeated use 24,40 contributed to the insensitivity of the 
instrument to pain. 
 Measurement of %BWdist as a means of describing limb use or presumed limb 
pain has been described in the literature.  Static body weight distribution was first evaluated 
using pressure sensitive walkway equipment.  In normal dogs, measurements of %BWdist were 
consistent from one week to the next, provided handling technique was consistent.25 In dogs 
recovering from total hip replacement, %BWdist to the operated limb increased at 3, 6 and 12 
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months after surgery, although without simultaneous pain scoring, it was not possible to 
conclude whether this change was related to a decrease in limb pain over time or simply a 
change in limb use. In another study, %BWdist was shown to be as sensitive as traditional ground 
reaction forces, vertical impulse and peak vertical force, for evaluating limb use in dogs before 
and months after total hip replacement.27  
More recent research measuring %BWdist has made use of a weight distribution platform 
as a smaller and less expensive alternative to pressure sensitive walkway equipment. 
Measurement of %BWdist using a weight distribution platform was found to be accurate 
compared to a pressure sensitive walkway,28 sensitive to and specific for limb lameness and 
orthopedic disease29, and repeatable for paired same-day or next-day measurements in dogs with 
hind limb lameness.41 To our knowledge, the present study is the first to statistically compare 
subjective pain scores with %BWdist.  We found no linear correlation between these outcome 
measures.  There are several possible explanations for this.  
Once a dog off-loads its limb to the point of being non-weight bearing, we lose the ability 
to assign any number besides zero to quantify their level of pain.  We observed many dogs to be 
non-weight bearing after surgery, and some remained non-weight bearing for the remainder of 
our study. It would be inaccurate to assume that non-weight bearing dogs, all described by 
%BWdist = 0, are equally painful in those limbs. During individual stance analysis sessions, we 
observed some variability in a patient’s willingness to bear weight on their operated limb. A 
limitation of the study is that we did not attempt to investigate this phenomenon.  Another 
limitation was the relatively infrequent postoperative measurement of %BWdist (4, 12, 24 and 48 
hours) compared with the frequency of pain scoring (2, 4, 8, 12, 20, 24, 32, 40 and 48 hours).  In 
this way, we may have missed opportunities for %BWdist to describe pain. Finally, we observed 
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in some dogs a preference for sitting or laying down on the weight distribution platform, which 
was slightly elevated and softer than the surrounding floor. For these dogs, obtaining valid stance 
data required many passes over the platform.  This brings into question the practicality of using 
this equipment to measure %BWdist. Using a weight distribution platform that is less tempting to 
dogs as a place of rest could make data collection more efficient.  
 We conclude that in this population of dogs recovering from TPLO and receiving 
postoperative carprofen, there was no difference between overall treatment success, relative 
rescue analgesia requirement, CMPS-SF pain scores, or %BWdist in dogs that received surgical 
wound infiltration with LB compared with saline placebo.  %BWdist holds promise as an 
objective outcome measure for acute orthopedic surgical pain and the design of a firmer, lower-
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Table 1 Population frequencies for variable relevant to postoperative pain assessment in 
the LB and saline treatment groups 
 
 LB (n = 15) Saline placebo (n = 17) Chi square p-value 
 
Recent carprofen use  
(# of dogs)   
4 7 0.39 
 
Stifle arthrotomy 
performed (# of dogs) 
10 13 0.54 
 
Meniscal debridement 
performed (# of dogs) 
 
5 3 0.31 















Table 2 Median (range) pain scores assigned  by use of the CMPS-SF for dogs receiving LB 
(n=15) or saline placebo (n = 17) 
 
 
 LB (n = 15) Saline placebo (n = 17)  
 
 
Pain score Number of dogs Pain score Number of dogs p value 
Preoperative 
baseline 




     
2 4 (1-11) 15 3 (1-11) 17 0.76 
4 3 (2-4) 13 3 (1-5) 13 0.76 
8 2 (1-5) 13 2 (1-12) 13 0.49 
12 2 (1-5) 13 2 (1-4) 12 0.37 
20 2 (1-4) 13 1.5 (1-4) 12 0.94 
24 1 (1-2) 13 1 (1-3) 12 0.48 
32 1 (1-2) 13 1 (1-3) 12 0.91 
40 1 (1-2) 13 1 (1-2) 12 0.98 
48 1 (1-2) 13 1 (1-2) 12 0.79 
      
(abbreviations: CMPS-SF, Glasgow composite mean pain score, short form; LB, liposomal bupivacaine) 









Table 3 Success/failure analysis results, where dogs requiring rescue analgesia at any 
postoperative timepoint (0 to 48 hours) were defined as treatment failures 
 
 
 LB (n = 15) Saline placebo (n = 17) Chi square p-value 
 









(abbreviations: LB, liposomal bupivacaine) 
 
 
Table 4 Mean (standard deviation) for %BW dist values for dogs receiving LB (n = 15) or saline 
placebo (n = 17) 
 
 
 LB (n = 15) Saline placebo (n = 17)  
 
 
%BWdist Number of dogs %BWdist Number of dogs P value 
Preoperative 
baseline 




     
4 3.9 (4.0) 13 1.6 (1.8) 12a 0.08 
12 2.9 (5.0) 13 1.8 (2.8) 12 0.07 
24 3.3 (3.4) 13 2.4 (3.1) 12 0.50 
48 2.4 (2.5) 11b 4.8 (3.7) 12 0.37 
      
(abbreviations: %BWdist, percent of total body weight distributed to the operated leg; LB, liposomal 
bupivacaine) For dogs requiring rescue analgesia, concurrent and subsequent measurements of 
%BWdist were excluded from statistical analyses. aData point missing for one dog who was too sedate to 
stand but did not require rescue analgesia. bData points are missing for two dogs that refused to stand 
(in favor of sitting) on the weight distribution platform but did not require rescue analgesia. 
 
